Terumo BCT and Marker Therapeutics Receive the US FDA’s Emergency Use Authorization for their Purification Device to Treat COVID-19

 Terumo BCT and Marker Therapeutics Receive the US FDA’s Emergency Use Authorization for their Purification Device to Treat COVID-19

Terumo BCT and Marker Therapeutics Receive the US FDA’s Emergency Use Authorization for their Purification Device to Treat COVID-19

Shots:

  • The US FDA has granted EUA to Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients aged ≥18yrs. with confirmed COVID-19 and are admitted to the ICU with confirmed or imminent respiratory failure to reduce pro-inflammatory cytokine levels
  • The device works by reducing the number of cytokines and other inflammatory mediators in the blood, filter it and return the filtered blood to the patient
  • The two companies collaborate to combine their existing technologies for providing a unique solution for the treatment of acute respiratory failure in COVID-19

Click here to­ read full press release/ article | Ref: Terumo BCT | Image: Terumo BCT

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post